Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 27 May 2017
At a glance
- Drugs Galunisertib (Primary) ; Capecitabine; Fluorouracil
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 19 May 2017 Status changed from not yet recruiting to recruiting.
- 14 Jun 2016 Planned initiation date changed from 1 Feb 2016 to 1 Jun 2016.
- 25 Feb 2016 New trial record